

Press Release

Jubilant HollisterStier Announces Multi-Million Dollar Award for the manufacture of Sterile Parenteral Products

Noida, (UP) India, February 22, 2012

Jubilant HollisterStier, a subsidiary of Jubilant Life Sciences, announced today that its Contract Manufacturing & Services division has recently secured contracts with four innovator life science companies for the commercial manufacturing of sterile parenteral products for sale in the United States and Europe. These agreements will be executed at its Spokane, Washington facility for contract manufacturing of products ranging from liquid to lyophilization presentations, across a variety of patient indications. The total value of these contracts is over US \$ 90 million to be delivered over a 5 year period. Commercial transfer to the Jubilant HollisterStier manufacturing facility has commenced for all contracts.

“We have successfully helped provide safe and effective products to innovator Pharmaceutical and Biotechnology companies over the years and are committed to do so for these products as well. We are pleased to offer our support in the development and manufacture of highly complex products through the application of leading scientific solutions and utmost dedication to quality and customer service. This expansion of our globally leading parenteral manufacturing capabilities is a further outcome of our strategy to extend our offering across products and geographies.” said *Marcelo Morales, Chief Executive Officer, Jubilant HollisterStier.*

Commenting on the multi-million dollar award, *Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences* said, **“We are pleased with signing of these long term contracts with innovator pharma companies to serve the regulated markets of US and Europe and is a direct result of our increased business development efforts leading to higher utilization of our existing capacity. Jubilant is one of the leading manufacturers of sterile both liquid and lyophilized products in North America.”**

About Jubilant HollisterStier

Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and life sciences company headquartered in India. Through its Contract Manufacturing Services division it provides its customers global manufacturing services for aseptically fill liquid and lyophilized products, semi-solid and solid dosage forms at its facilities in the United States, Canada, and India. Jubilant HollisterStier offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. Jubilant HollisterStier is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities. For more info about Jubilant HollisterStier, visit jublHS.com.



About Jubilant Life Sciences

Jubilant Life Sciences Limited is an integrated Pharma and Life Sciences Company. It is the largest Custom Research and Manufacturing Services (CRAMS) player and a leading Drug Discovery and Development Solution provider out of India. The Company provides Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities and a team of 6,200 multicultural people across the globe, the Company is committed to deliver value to its customers spread across 75 countries. The Company is well recognized as a 'Partner of Choice' by leading life sciences companies worldwide. For more info: www.jubl.com

For more information please contact:

For Media

Sudhakar Safaya

Jubilant Life Sciences Limited

+91 - 0120 4361034

Email - sudhakar_safaya@jubl.com

For Investors

Nidhi Aggarwal

Jubilant Life Sciences Limited

Ph: +91-120 4361002

E-mail: nidhi_aggarwal@jubl.com

Siddharth Rangnekar

Citigate Dewe Rogerson

Tel: +91 -22 6645 1209

E-mail: siddharth@cdr-india.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.